Friday, October 16
Healthupdated today

Does the FDA approve Summit's ivonescimab for lung cancer?

Will the FDA approve Summit Therapeutics' ivonescimab, in combination with chemotherapy, for previously treated EGFR-mutated non-small-cell lung cancer by its November 14, 2026 PDUFA target action date?

45% yes — FDA approves ivonescimab

Close to a coin flip, leaning slightly against approval on schedule — Summit's own cited OS data is described by several analysts as not clearly meeting the FDA's stated statistical-significance bar, even as the company and WCLC data presentation lean bullish

The case for approval: HARMONi met its primary endpoint (progression-free survival) back in 2024, updated Western-patient OS data trends the same direction as the Asian cohort, the related HARMONi-2 trial's clearly significant OS win over Keytruda feeds broader confidence in the molecule's underlying mechanism, and Summit has continued presenting updated data at major conferences (WCLC) rather than withdrawing or delaying the filing. The case against: the FDA specifically told Summit a statistically significant OS benefit was required, the Nov 14 filing rests on HARMONi (not the stronger HARMONi-2 data), several analysts and outlets describe the OS result as not bearing clear statistical significance given multiplicity adjustments, Summit's own updated analysis is a nominal (not formally pre-specified-threshold-crossing) p-value of 0.0332, and a comparable prior precedent (Eli Lilly's 2022 CRL for a China-only PD-1 trial) shows the FDA's skepticism toward single-region trial data generally.

Resolves Nov 14, 2026 · PDUFA target action date for Summit Therapeutics' BLA covering ivonescimab plus chemotherapy in previously treated, EGFR-mutated non-small-cell lung cancer, based on Phase 3 HARMONi trial data

The FDA accepted Summit's BLA on Jan 29, 2026, based on the Phase 3 HARMONi trial in EGFR-mutated NSCLC patients who had progressed on TKI therapy, setting a Nov 14, 2026 PDUFA date. The regulatory crux is overall survival: the FDA has told Summit that a statistically significant OS benefit is necessary to support approval in this setting, and updated Western-patient data presented at WCLC on Sept 15, 2026 showed an OS hazard ratio of 0.78 with a nominal p-value of 0.0332 — consistent with the Asian-patient results but, per several analysts, not clearly crossing the pre-specified, multiplicity-adjusted significance boundary the FDA itself set as the bar. Separately, Akeso's related HARMONi-2 trial (first-line, China-only, not the basis for this specific US filing) reported a larger, more clearly significant OS edge over Keytruda (HR 0.73, p=0.009) in September 2026, feeding bullish investor sentiment around the molecule generally even though it isn't the dataset the Nov 14 decision turns on. Grade 3+ treatment-related adverse events ran higher on ivonescimab than on comparator arms in the trials reported to date (29.4% vs. 15.6% in HARMONi-2).

The FDA either approves the BLA (with or without post-marketing conditions) by its Nov 14, 2026 target date, or it issues a Complete Response Letter or delays the decision — a discrete regulatory action with no partial outcome.

Researched Oct 16, 2026 · tracked since Oct 16, 2026

Build a position

market 45%you 45%no edge

You agree with the market.

Nothing here has positive expected value — the price already reflects this view. Move the slider to where you think the odds actually are.

Take a side

FDA approves ivonescimabthis is “yes”

HARMONi already met its primary PFS endpoint, updated Western-patient OS data trends consistently with the Asian cohort, and the related HARMONi-2 trial's clearly significant OS win over Keytruda bolsters confidence in the molecule's underlying mechanism.

Long
SMMT Summit Therapeutics Inc.The BLA sponsor; approval validates ivonescimab's first US indication and a franchise built on multiple ongoing trials, while a CRL would be a major, binary setback for the company's lead asset.
Long
XBI SPDR S&P Biotech ETFBroad biotech-sentiment barometer; a high-profile approval or rejection of a closely-watched, binary-catalyst oncology asset moves sector sentiment at the margin.
Long
IBB iShares Biotechnology ETFA second, more large-cap-weighted biotech sector proxy; moves with the same diluted sentiment logic as XBI but with a different constituent mix.
Short
MRK Merck & Co., Inc.Maker of Keytruda, the dominant checkpoint-inhibitor franchise in NSCLC and ivonescimab's most direct target of displacement; an approval intensifies competitive pressure, while a CRL removes a near-term threat.
Short
BMY Bristol-Myers Squibb CompanyMaker of Opdivo, a second major checkpoint-inhibitor franchise in NSCLC; benefits similarly to Merck, at a smaller scale, from one fewer approved competitor in the same indication.
Short
AZN AstraZeneca PLCMaker of Imfinzi and a major NSCLC-franchise competitor; a rejection or delay for ivonescimab eases competitive pressure on AstraZeneca's existing lung-cancer portfolio.

Worth knowing: The FDA explicitly told Summit it needs a statistically significant OS benefit, and several analysts read the updated nominal p=0.0332 result as not clearly meeting that bar — don't mistake a positive data presentation for a result that has cleared the agency's own stated threshold.

FDA delays or rejects ivonescimab

The Nov 14 filing rests on HARMONi, not the stronger HARMONi-2 data, Summit's own cited OS result is a nominal (not clearly pre-specified-threshold-crossing) p-value, and a comparable precedent — Eli Lilly's 2022 CRL for a China-only PD-1 trial — shows FDA skepticism toward single-region data generally.

Short
SMMT Summit Therapeutics Inc.The BLA sponsor; approval validates ivonescimab's first US indication and a franchise built on multiple ongoing trials, while a CRL would be a major, binary setback for the company's lead asset.
Short
XBI SPDR S&P Biotech ETFBroad biotech-sentiment barometer; a high-profile approval or rejection of a closely-watched, binary-catalyst oncology asset moves sector sentiment at the margin.
Short
IBB iShares Biotechnology ETFA second, more large-cap-weighted biotech sector proxy; moves with the same diluted sentiment logic as XBI but with a different constituent mix.
Long
MRK Merck & Co., Inc.Maker of Keytruda, the dominant checkpoint-inhibitor franchise in NSCLC and ivonescimab's most direct target of displacement; an approval intensifies competitive pressure, while a CRL removes a near-term threat.
Long
BMY Bristol-Myers Squibb CompanyMaker of Opdivo, a second major checkpoint-inhibitor franchise in NSCLC; benefits similarly to Merck, at a smaller scale, from one fewer approved competitor in the same indication.
Long
AZN AstraZeneca PLCMaker of Imfinzi and a major NSCLC-franchise competitor; a rejection or delay for ivonescimab eases competitive pressure on AstraZeneca's existing lung-cancer portfolio.

Worth knowing: HARMONi-2's much more clearly significant OS win over Keytruda (even though it's a different trial) has shifted broader investor and analyst sentiment on the molecule bullish — don't assume today's skepticism about this specific filing's statistics will necessarily persist if the FDA extends or requests more data rather than issuing an outright CRL.

5 sources, leaning both ways